Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Update

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a significant increase in short interest in August. As of August 31st, there was short interest totaling 34,593 shares, an increase of 411.8% from the August 15th total of 6,759 shares. Currently, 2.4% of the company’s stock are short sold. Based on an average daily volume of 31,550 shares, the short-interest ratio is presently 1.1 days.

Global X Genomics & Biotechnology ETF Stock Up 0.8%

Global X Genomics & Biotechnology ETF stock traded up $0.50 during midday trading on Friday, reaching $62.47. The company’s stock had a trading volume of 5,895 shares, compared to its average volume of 17,958. Global X Genomics & Biotechnology ETF has a fifty-two week low of $36.13 and a fifty-two week high of $68.00. The company has a market cap of $91.20 million, a P/E ratio of -26.70 and a beta of 1.19. The business has a 50-day simple moving average of $59.41 and a 200-day simple moving average of $51.42.

Global X Genomics & Biotechnology ETF Dividend Announcement

The firm also recently disclosed a semiannual dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 29th were issued a $0.0579 dividend. The ex-dividend date was Monday, June 29th. This represents a dividend yield of 20.0%. Global X Genomics & Biotechnology ETF’s dividend payout ratio is presently -27.35%.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE raised its holdings in Global X Genomics & Biotechnology ETF by 67.8% during the first quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock worth $5,240,000 after purchasing an additional 48,394 shares in the last quarter. Sei Investments Co. boosted its holdings in Global X Genomics & Biotechnology ETF by 110.4% in the 2nd quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after purchasing an additional 12,105 shares in the last quarter. Jane Street Group LLC boosted its holdings in Global X Genomics & Biotechnology ETF by 7.7% in the 1st quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock valued at $1,143,000 after purchasing an additional 10,308 shares in the last quarter. Wealth Management Partners LLC acquired a new position in Global X Genomics & Biotechnology ETF during the 1st quarter worth approximately $244,000. Finally, Smartleaf Asset Management LLC increased its position in Global X Genomics & Biotechnology ETF by 30.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after purchasing an additional 4,615 shares during the period. Institutional investors and hedge funds own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.